3,5 Diiodo-L-Thyronine (T2) Does Not Prevent Hepatic Steatosis or Insulin Resistance in Fat-Fed Sprague Dawley Rats
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Thyroid hormone mimetics are alluring potential therapies for diseases like dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and insulin resistance. Though diiodothyronines are thought inactive, pharmacologic treatment with 3,5- Diiodo-L-Thyronine (T2) reportedly reduces hepatic lipid content and improves glucose tolerance in fat-fed male rats. To test this, male Sprague Dawley rats fed a safflower-oil based high-fat diet were treated with T2 (0.25 mg/kg-d) or vehicle. Neither 10 nor 30 days of T2 treatment had an effect on weight, adiposity, plasma fatty acids, or hepatic steatosis. Insulin action was quantified in vivo by a hyperinsulinemic-euglycemic clamp. T2 did not alter fasting plasma glucose or insulin concentration. Basal endogenous glucose production (EGP) rate was unchanged. During the clamp, there was no difference in insulin stimulated whole body glucose disposal. Insulin suppressed EGP by 60% ± 10 in T2-treated rats as compared with 47% ± 4 suppression in the vehicle group (p = 0.32). This was associated with an improvement in hepatic insulin signaling; insulin stimulated Akt phosphorylation was ~2.5 fold greater in the T2-treated group as compared with the vehicle-treated group (p = 0.003). There was no change in expression of genes thought to mediate the effect of T2 on hepatic metabolism, including genes that regulate hepatic lipid oxidation (ppara, carnitine palmitoyltransferase 1a), genes that regulate hepatic fatty acid synthesis (srebp1c, acetyl coa carboxylase, fatty acid synthase), and genes involved in glycolysis and gluconeogenesis (L-pyruvate kinase, glucose 6 phosphatase). Therefore, in contrast with previous reports, in Sprague Dawley rats fed an unsaturated fat diet, T2 administration failed to improve NAFLD or whole body insulin sensitivity. Though there was a modest improvement in hepatic insulin signaling, this was not associated with significant differences in hepatic insulin action. Further study will be necessary before diiodothyronines can be considered an effective treatment for NAFLD and dyslipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver
Du, K., Herzig, S., Kulkarni, R. N., & Montminy, M. (2003) · Science · doi:10.1126/science.1079817 · Cited by 842
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
Self-citationSamuel, V. T., Liu, Z.-X., Wang, A., Beddow, S. A., Geisler, J. G., Kahn, M., Zhang, X.-M., Monia, B. P., Bhanot, S., & Shulman, G. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30400 · Cited by 497
Self-citationThyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation
Liu, Y.-Y., & Brent, G. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.004 · Cited by 218
3,5‐Diiodo‐ L ‐thyronine powerfully reduces adiposity in rats by increasing the burning of fats
Lanni, A., Moreno, M., Lombardi, A., De Lange, P., Silvestri, E., Ragni, M., Farina, P., Baccari, G. C., Fallahi, P., Antonelli, A., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-3977fje · Cited by 134
Moreno, M., Lanni, A., Lombardi, A., & Goglia, F. (1997) · The Journal of Physiology · doi:10.1111/j.1469-7793.1997.529bb.x · Cited by 123
Nonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-Diiodo-L-Thyronine in Rats
de Lange, P., Cioffi, F., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., De Matteis, R., Lionetti, L., Mollica, M. P., Goglia, F., et al. (2011) · Diabetes · doi:10.2337/db11-0207 · Cited by 106
Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway
Goldberg, I. J., Huang, L.-S., Huggins, L. A., Yu, S., Nagareddy, P. R., Scanlan, T. S., & Ehrenkranz, J. R. (2012) · Endocrinology · doi:10.1210/en.2012-1572 · Cited by 80
3,5-T2 Is an Alternative Ligand for the Thyroid Hormone Receptor β1
Mendoza, A., Navarrete-Ramírez, P., Hernández-Puga, G., Villalobos, P., Holzer, G., Renaud, J. P., Laudet, V., & Orozco, A. (2013) · Endocrinology · doi:10.1210/en.2013-1030 · Cited by 76
3,5-Diiodo-L-thyronine (T2) has selective thyromimetic effects in vivo and in vitro
Ball, S., Sokolov, J., & Chin, W. (1997) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0190137 · Cited by 75
Cited by
The colorful diversity of thyroid hormone metabolites
Köhrle, J. (2019) · European Thyroid Journal · doi:10.1159/000497141 · Cited by 67
3,5-diiodothyronine: a novel thyroid hormone metabolite and potent modulator of energy metabolism
Senese, R., de Lange, P., Petito, G., Moreno, M., Goglia, F., & Lanni, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00427 · Cited by 52
Massolt, E. T., van der Windt, M., Korevaar, T. I. M., Kam, B. L. R., Burger, J. W., Franssen, G. J. H., Lehmphul, I., Köhrle, J., Visser, W. E., & Peeters, R. P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13101 · Cited by 47
Direct and rapid effects of 3,5-diiodo-L-thyronine (T2)
Moreno, M., Giacco, A., Di Munno, C., & Goglia, F. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.012 · Cited by 25
Metadata
- Authors
- Vatner, D. F., Snikeris, J., Popov, V., Perry, R. J., Rahimi, Y., & Samuel, V. T.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-20
- Volume
- 10
- Issue
- 10
- Pages
- e0140837
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1807014225
- Cited by
- 19
- References
- 12
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 3,5 Diiodo-L-Thyronine (T2) Does Not Prevent Hepatic Steatosis or Insulin Resistance in Fat-Fed Sprague Dawley Rats. https://app.cochat.ai/papers/10.1371/journal.pone.0140837
- The paper
- Vatner, D. F., Snikeris, J., Popov, V., Perry, R. J., Rahimi, Y., & Samuel, V. T. (2015). 3,5 Diiodo-L-Thyronine (T2) Does Not Prevent Hepatic Steatosis or Insulin Resistance in Fat-Fed Sprague Dawley Rats. PLOS ONE. https://doi.org/10.1371/journal.pone.0140837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.